Modality
Degrader
MOA
Menini
Target
WRN
Pathway
Proteasome
BCCHuntington's
Development Pipeline
Preclinical
~Mar 2023
→ ~Jun 2024
Phase 1
Sep 2024
→ Jun 2031
Phase 1Current
NCT05253672
1,400 pts·Huntington's
2024-09→2031-06·Active
1,400 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-195.2y awayInterim· Huntington's
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Active
Catalysts
Interim
2031-06-19 · 5.2y away
Huntington's
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05253672 | Phase 1 | Huntington's | Active | 1400 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| TSH-7567 | Taysha Gene | Phase 1/2 | WRN |